Catalyst Brief

← Calendar

ReadoutIn window

EMD Serono Research & Development Institute, Inc. — Avelumab

Phase 3 primary completion: Avelumab Program Rollover Study.

Date
Nov 2026
Type
Readout
Indication
Solid Tumors

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.